For older glucose-lowering agents, such as insulin and sulfonylureas, there is insufficient evidence indicating the effects on HF outcomes in patients with diabetes and with established HF due to the lack of randomized controlled trials. The gene discussed is INS; the disease is diabetes mellitus.